Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALLO-316 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALLO-647, ALLO-316 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALLO-316 | GENETIC | ALLO-316 is an allogeneic CAR T cell therapy targeting CD70 |
| ALLO-647 | BIOLOGICAL | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: * Histologically confirmed renal cell carcinoma with a predominant clear cell component. * Must have received a checkpoint inhibitor and a VEGF inhibitor in the advanced and/or metastatic setting. * At least one measurable lesion as defined by RECIST version 1.1 * Eastern Cooper...
ALLO-316 is an investigational gene therapy being studied for the treatment of advanced or metastatic clear cell renal cell carcinoma. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated in a clinical trial to assess its safety and efficacy in this patient population.
ALLO-316 targets CD70, a protein expressed on certain cancer cells. By targeting CD70, the therapy is designed to recognize and attack CD70-positive tumor cells. This mechanism is being investigated in the context of advanced or metastatic clear cell renal cell carcinoma, where CD70 expression may play a role in disease progression.
ALLO-316 is being developed by Allogene Therapeutics, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol ALLO. The company is conducting clinical research on this investigational therapy for advanced or metastatic clear cell renal cell carcinoma.
ALLO-316 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received FDA approval. The therapy has been granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations by the FDA, which are intended to expedite the development and review of promising therapies.
ALLO-316 is being studied in a Phase 1 clinical trial with the identifier NCT04696731. This trial is titled 'Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma' and is currently active but not recruiting. The study is enrolling approximately 120 participants in the United States.
ALLO-316 is the primary name for this investigational therapy. No alternative names have been reported for this drug. It is a gene therapy being developed by Allogene Therapeutics for the treatment of advanced or metastatic clear cell renal cell carcinoma.